Raptiva efalizumab: Phase III; Under review to treat psoriasis

In a 12-week, open-label extension of a double-blind, placebo-controlled U.S. Phase III study, 161 of

Read the full 152 word article

How to gain access

Continue reading with a
two-week free trial.